U.S. flag

An official website of the United States government

NM_000500.9(CYP21A2):c.874G>A (p.Gly292Ser) AND not provided

Germline classification:
Pathogenic/Likely pathogenic (3 submissions)
Last evaluated:
Aug 29, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000711386.9

Allele description [Variation Report for NM_000500.9(CYP21A2):c.874G>A (p.Gly292Ser)]

NM_000500.9(CYP21A2):c.874G>A (p.Gly292Ser)

Genes:
LOC106780800:CYP21A2 recombination region [Gene]
CYP21A2:cytochrome P450 family 21 subfamily A member 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
6p21.33
Genomic location:
Preferred name:
NM_000500.9(CYP21A2):c.874G>A (p.Gly292Ser)
HGVS:
  • NC_000006.12:g.32040140G>A
  • NG_007941.3:g.6836G>A
  • NG_008337.2:g.74235C>T
  • NG_045215.1:g.2369G>A
  • NM_000500.9:c.874G>AMANE SELECT
  • NM_001128590.4:c.784G>A
  • NM_001368143.2:c.469G>A
  • NM_001368144.2:c.469G>A
  • NP_000491.4:p.Gly292Ser
  • NP_001122062.3:p.Gly262Ser
  • NP_001355072.1:p.Gly157Ser
  • NP_001355073.1:p.Gly157Ser
  • LRG_829t1:c.874G>A
  • LRG_829:g.6836G>A
  • LRG_829p1:p.Gly292Ser
  • NC_000006.11:g.32007917G>A
  • NM_000500.7:c.874G>A
Protein change:
G157S; GLY292SER
Links:
OMIM: 613815.0007; dbSNP: rs201552310
NCBI 1000 Genomes Browser:
rs201552310
Molecular consequence:
  • NM_000500.9:c.874G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001128590.4:c.784G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001368143.2:c.469G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001368144.2:c.469G>A - missense variant - [Sequence Ontology: SO:0001583]
Observations:
1

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000841749Athena Diagnostics
criteria provided, single submitter

(Athena Diagnostics Criteria)
Pathogenic
(Jan 3, 2018)
germlineclinical testing

PubMed (14)
[See all records that cite these PMIDs]

SCV001449930Clinical Genetics and Genomics, Karolinska University Hospital
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jun 1, 2018)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002234382Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Aug 29, 2023)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyes1not providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations.

Wedell A, Ritzén EM, Haglund-Stengler B, Luthman H.

Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7232-6.

PubMed [citation]
PMID:
1496017
PMCID:
PMC49680

Three-dimensional structure of steroid 21-hydroxylase (cytochrome P450 21A2) with two substrates reveals locations of disease-associated variants.

Zhao B, Lei L, Kagawa N, Sundaramoorthy M, Banerjee S, Nagy LD, Guengerich FP, Waterman MR.

J Biol Chem. 2012 Mar 23;287(13):10613-10622. doi: 10.1074/jbc.M111.323501. Epub 2012 Jan 18.

PubMed [citation]
PMID:
22262854
PMCID:
PMC3323056
See all PubMed Citations (19)

Details of each submission

From Athena Diagnostics, SCV000841749.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (14)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Clinical Genetics and Genomics, Karolinska University Hospital, SCV001449930.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot provided1not providednot providednot provided

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002234382.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 292 of the CYP21A2 protein (p.Gly292Ser). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This missense change has been observed in individual(s) with salt-wasting and simple virilizing congenital adrenal hyperplasia due to 21-hydroxylase deficiency (PMID: 9497336, 26206692, 34821488). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 12156). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CYP21A2 protein function. Experimental studies have shown that this missense change affects CYP21A2 function (PMID: 9497336, 28539365). This variant disrupts the p.Gly292 amino acid residue in CYP21A2. Other variant(s) that disrupt this residue have been observed in individuals with CYP21A2-related conditions (PMID: 10364682, 12915679), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024